Cossu Rocca, Maria http://orcid.org/0000-0002-5780-3774
Lorini, Luigi
Szturz, Petr
Bossi, Paolo
Vermorken, Jan B.
Article History
Accepted: 14 December 2022
First Online: 30 January 2023
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Dr. M. Cossu Rocca: Advisory board or conference honoraria with Merck Sharp & Dohme. Dr. L. Lorini: Nothing to declare. Dr. P. Szturz: has had in the last 3 years or has advisory relationships with Merck-Serono, Servier and BMS. Dr. P. Bossi: Advisory board or conference honoraria: Merck, Sanofi-Regeneron, Merck Sharp & Dohme, Sun Pharma, Angelini, Nestlè. Dr. J. B. Vermorken participates in advisory boards of: Astellas, Merck Sharp & Dome Corp, Nanobiotix, NEKTAR, PCI Biotech, WntResearch, SMS-Oncology; Lecturer fee from: Merck-Serono, MSD.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Authors MCR, LL and PB contributed equally to the primary concept and to the draft of the manuscript. Authors JBV and PS revised the manuscript. All Authors read and approved the final manuscript. Finally all Authors agree to be accountable for their work.